These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 979066)

  • 1. The effect of saralasin (1sar-8-ala-angiotensin II) on blood pressure in patients with Cushing's syndrome.
    Vetter W; Vetter H; Beckerhoff R; Redlich B; Cottier P; Siegenthaler W
    Klin Wochenschr; 1976 Jul; 54(14):661-3. PubMed ID: 979066
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evidence for an angiotensinogenic mechanism of the hypertension of Cushing's syndrome.
    Dalakos TG; Elias AN; Anderson GH; Streeten DH; Schroeder ET
    J Clin Endocrinol Metab; 1978 Jan; 46(1):114-8. PubMed ID: 752014
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effects of the angiotensin II antagonist saralasin on blood pressure and plasma aldosterone in man in relation to the prevailing plasma angiotensin II concentration.
    Brown JJ; Brown WC; Fraser R; Lever AF; Morton JJ; Robertson JI; Rosei EA; Trust PM
    Prog Biochem Pharmacol; 1976; 12():230-41. PubMed ID: 1019166
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Effect of the angiotensin antagonist saralasin (1-sar-8-ala-angiotensin II) on the blood pressure in secondary hypertension].
    Beckerhoff R; Vetter W; Furrer J; Tuma J; Zàruba K; Vetter H; Siegenthaler W
    Schweiz Med Wochenschr; 1976 Dec; 106(49):1738-41. PubMed ID: 1013696
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effects of saralasin, an angiotensin II antagonist, on blood pressure and the renin-angiotensin-aldosterone system in normal and hypertensive subjects.
    Brown JJ; Brown WC; Fraser R; Lever AF; Morton JJ; Robertson JI; Rosei EA; Trust PM
    Aust N Z J Med; 1976 Aug; 6(3 Suppl):48-52. PubMed ID: 1071403
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of 1-sar-8-ala-angiotensin II on arterial pressure, renin and aldosterone in hypertension.
    Fagard R; Lijnen P; Amery A; Reybrouck T
    Contrib Nephrol; 1978; 11():175-8. PubMed ID: 699588
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Comparison of effects of two angiotensin II antagonists on blood pressure, heart rate, plasma renin activity, and plasma aldosterone concentration in the same hypertensive patients].
    Higuma K; Fujishima S; Shionoiri H; Tochikubo O; Uneda S; Fujiki Y; Kaneko Y
    Nihon Jinzo Gakkai Shi; 1984 Apr; 26(4):425-35. PubMed ID: 6381833
    [No Abstract]   [Full Text] [Related]  

  • 8. Exaggerated blood pressure response to angiotensin II in patients with Cushing's syndrome due to adrenocortical adenoma.
    Yasuda G; Shionoiri H; Umemura S; Takasaki I; Ishii M
    Eur J Endocrinol; 1994 Dec; 131(6):582-8. PubMed ID: 7804440
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of the angiotensin II antagonist saralasin on plasma aldosterone concentration and on blood pressure before and during sodium depletion in normal subjects.
    Agabiti-Rosei E; Brown JJ; Brown WC; Fraser R; Trust PM; Lever AF; Morton JJ; Robertson JI
    Clin Endocrinol (Oxf); 1979 Mar; 10(3):227-34. PubMed ID: 455738
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiovascular, renal and endocrine effects of alpha-human atrial natriuretic peptide in patients with Cushing's syndrome and primary aldosteronism.
    Fujio N; Ohashi M; Nawata H; Kato K; Matsuo H; Ibayashi H
    J Hypertens; 1989 Aug; 7(8):653-9. PubMed ID: 2553806
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of blockade of angiotensin II on blood pressure, renin and aldosterone in cirrhosis.
    Schroeder ET; Anderson GH; Goldman SH; Streeten DH
    Kidney Int; 1976 Jun; 9(6):511-9. PubMed ID: 940284
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Corticoid secretion in primary aldosteronism. II. The renin releasing test and the angiotensin II analog infusion test (author's transl)].
    Nigawara K; Yagihashi Y; Kogawa T; Sugawara S; Kawamata A; Hitomi H; Tulachan Y; Funyu T; Terayama Y; Furusawa M; Morita S; Kido K; Tanaka T; Eba H
    Nihon Naibunpi Gakkai Zasshi; 1980 Jan; 56(1):47-56. PubMed ID: 6987096
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of an angiotensin antagonist (saralasin) on arterial pressure and plasma aldosterone in hemodialysis-resistant hypertensive patients.
    Mimran A; Shaldon S; Barjon P; Mion C
    Clin Nephrol; 1978 Feb; 9(2):63-7. PubMed ID: 639368
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of angiotensin II blockade by saralasin (1-Sar-8-Ala-angiotensin II) in normal man.
    Ibsen H; Kappelgaard AM; Nielsen MD; Giese J
    Eur J Clin Pharmacol; 1978 Nov; 14(3):171-6. PubMed ID: 729612
    [No Abstract]   [Full Text] [Related]  

  • 15. [Saralasin-induced changes of blood pressure, renin and aldosterone in essential and renal hypertension (author's transl)].
    Beyer J; Liebau G; Steiner B; Hayduk K
    Klin Wochenschr; 1978 Sep; 56(17):859-64. PubMed ID: 713415
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pathogenetic aspects of hypertension in Cushing's syndrome.
    Tenschert W; Baumgart P; Greminger P; Vetter W; Vetter H
    Cardiology; 1985; 72 Suppl 1():84-90. PubMed ID: 3902234
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changes of blood pressure, plasma renin activity and plasma aldosterone concentration following the infusion of Sar1-Ile8-angiotensin II in hypertensive, fluid and electrolyte disorders.
    Yamamoto T; Doi K; Ogihara T; Ichihara K; Hata T; Kumahara Y
    Prog Biochem Pharmacol; 1976; 12():174-89. PubMed ID: 1019163
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The use of saralasin in the recognition of angiotensinogenic hypertension.
    Streeten DH; Dalakos TG; Anderson GH
    Prog Biochem Pharmacol; 1976; 12():214-26. PubMed ID: 1019165
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of angiotensin-II blockade on systemic and hepatic haemodynamics and on the renin-angiotensin-aldosterone system in cirrhosis with ascites.
    Arroyo V; Bosch J; Mauri M; Ribera F; Navarro-López F; Rodés J
    Eur J Clin Invest; 1981 Jun; 11(3):221-9. PubMed ID: 6791942
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Changes in plasma norepinephrine after intravertebral artery infusion of saralasin in sodium depleted dogs.
    Arita M; Ueno Y; Suruda H; Mohara O; Nishio I; Masuyama Y
    Jpn Circ J; 1983 Mar; 47(3):336-41. PubMed ID: 6339771
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.